{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:27:31Z","timestamp":1754162851921,"version":"3.41.2"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Allogeneic hematopoietic cell transplantation (HCT) is a curative option for many for inborn errors of immunity (IEI). This review highlights recent progress in the field of HCT for IEI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Alternative donor transplantation continues to expand donor options for patients with IEI. Reduced intensity and reduced toxicity conditioning approaches are being investigated and optimized. Immunomodulatory bridging therapies are yielding impressive progress in outcomes for primary immune regulatory disorders (PIRD) but require further study in prospective trials. Single-institution, multicenter and consortium studies have improved our understanding of factors that affect overall outcomes in IEI and outcomes in Wiskott\u2013Aldrich syndrome (WAS), chronic granulomatous disease (CGD) and PIRD in particular. Data show that second HCT offers a viable chance of cure to some IEI patients. Late effects in IEI HCT survivors are being better characterized. Preclinical studies of chemo(radiation)-free HCT strategies hold promise for decreasing HCT toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Improvements in our understanding of HCT donor choice, conditioning regimen, immunomodulatory bridging therapies, diagnostic and post-HCT surveillance testing and late effects continue to yield advancements in the field of HCT for IEI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001407","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:57:01Z","timestamp":1727283421000},"page":"653-658","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hematopoietic cell transplantation for inborn errors of immunity: an update on approaches, outcomes and innovations"],"prefix":"10.1097","volume":"36","author":[{"given":"Olatundun","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human Inborn Errors of Immunity: 2022 update on the Classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/MOP.0000000000001292","article-title":"Progress in the field of hematopoietic stem cell-based therapies for inborn errors of immunity","volume":"35","author":"Arnold","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.2024024038","article-title":"Outcomes of HLA-mismatched HSCT with TCRalphabeta\/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity","volume":"144","author":"Lum","year":"2024","journal-title":"Blood"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/bloodadvances.2022009038","article-title":"Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival","volume":"7","author":"Martinez","year":"2023","journal-title":"Blood Adv"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10875-024-01669-x","article-title":"Cord blood transplantation for very early-onset inflammatory bowel disease caused by interleukin-10 receptor deficiency","volume":"44","author":"Wang","year":"2024","journal-title":"J Clin Immunol"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"101.e1","DOI":"10.1016\/j.jtct.2023.09.024","article-title":"Age impacts risk of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for non-severe combined immune deficiency inborn errors of immunity","volume":"30","author":"Fitch","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"e15083","DOI":"10.1111\/ctr.15083","article-title":"The impact of Treosulfan-based conditioning for inborn errors of immunity: is dose monitoring crucial?","volume":"37","author":"Ersoy","year":"2023","journal-title":"Clin Transplant"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"275.e18","DOI":"10.1016\/j.jaci.2023.10.018","article-title":"JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: An ESID\/EBMT-IEWP retrospective study","volume":"153","author":"Fischer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"704.e5","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaci.2023.05.016","article-title":"Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations","volume":"152","author":"Kunvarjee","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R12-20250730","article-title":"Gut immunomodulation with vedolizumab prior to allogeneic hematopoietic stem cell transplantation in pediatric patients with inflammatory bowel disease","volume":"30","author":"Chopra","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"1103080","DOI":"10.3389\/fimmu.2023.1103080","article-title":"Hematopoietic stem cell transplantation for inborn errors of immunity: 30-year single-center experience","volume":"14","author":"Dell\u2019Orso","year":"2023","journal-title":"Front Immunol"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10875-022-01403-5","article-title":"Impact of genetic diagnosis on the outcome of hematopoietic stem cell transplant in primary immunodeficiency disorders","volume":"43","author":"Forlanini","year":"2023","journal-title":"J Clin Immunol"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"335.e1","DOI":"10.1016\/j.jaci.2023.09.036","article-title":"Racial and ethnic disparities in early mortality among patients with inborn errors of immunity","volume":"153","author":"Ong","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2019002939","article-title":"Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report","volume":"135","author":"Burroughs","year":"2020","journal-title":"Blood"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood.2023021411","article-title":"Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival","volume":"143","author":"Vallee","year":"2024","journal-title":"Blood"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/blood.2022019586","article-title":"Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD","volume":"142","author":"Leiding","year":"2023","journal-title":"Blood"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.2020005590","article-title":"Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults","volume":"136","author":"Chiesa","year":"2020","journal-title":"Blood"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"1423.e2","DOI":"10.1016\/j.jaci.2024.01.013","article-title":"Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: a Primary Immune Deficiency Treatment Consortium study","volume":"153","author":"Grunebaum","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2022017667","article-title":"Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT","volume":"141","author":"Schuetz","year":"2023","journal-title":"Blood"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jaci.2023.08.004","article-title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency","volume":"152","author":"Taghizade","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jaci.2021.07.029","article-title":"Poor T-cell receptor beta repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution","volume":"149","author":"Delmonte","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2022.08.004","article-title":"Aberrant T-cell exhaustion in severe combined immunodeficiency survivors with poor T-cell reconstitution after transplantation","volume":"151","author":"Labrosse","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s10875-023-01549-w","article-title":"Outcome of second allogeneic HSCT for patients with inborn errors of immunity: retrospective study of 20 years\u2019 experience","volume":"43","author":"Mehta","year":"2023","journal-title":"J Clin Immunol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41409-022-01883-4","article-title":"Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity","volume":"58","author":"Laberko","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"513.e1","DOI":"10.1016\/j.jtct.2023.05.019","article-title":"CD3(+)TCRalphabeta\/CD19(+)-depleted mismatched family or unrelated donor salvage stem cell transplantation for graft dysfunction in inborn errors of immunity","volume":"29","author":"Ramanathan","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"582 e1","DOI":"10.1016\/j.jtct.2023.06.006","article-title":"Impact of graft function on health status and quality of life in very long-term survivors who received an HSCT for inborn errors of immunity, a prospective study of the CEREDIH","volume":"29","author":"Petit","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaci.2023.09.027","article-title":"Posttransplantation late complications increase over time for patients with SCID: a Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study","volume":"153","author":"Eissa","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"109942","DOI":"10.1016\/j.clim.2024.109942","article-title":"Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia","volume":"261","author":"Abraham","year":"2024","journal-title":"Clin Immunol"},{"key":"R31-20250730","first-page":"547.e5","article-title":"The diagnosis of severe combined immunodeficiency: implementation of the PIDTC 2022 Definitions","volume":"151","author":"Dvorak","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"341.e3","DOI":"10.1016\/j.jaci.2023.07.017","article-title":"Transplantation after CD45-ADC corrects Rag1 immunodeficiency in congenic and haploidentical settings","volume":"153","author":"Pala","year":"2024","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:03:55Z","timestamp":1753898635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001407","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"type":"print","value":"1040-8703"},{"type":"electronic","value":"1531-698X"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}